Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global ATD Market Portraiture
2.2. Global ATD Market, by Type of Anemia, 2017 (US$ Mn)
2.3. Global ATD Market, by Type of Drug, 2017 (US$ Mn)
2.4. Global ATD Market, by Geography, 2017 Vs 2026 (Value %)
Chapter 3. Global Anemia Treatment Drugs (ATD) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.2.1. Rising prevalence of anemia and complications related with diseases related to anemia
3.2.2. Increasing awareness related to anemia diagnosis and treatment especially in developing and under developed countries from Asia, Africa & South America
3.3. Challenges
3.3.1. Chronic anemia is treated with bone marrow transplantation or blood transfusion there no drug treatment available in the market
3.4. Opportunities
3.4.1. Strong pipeline with number of promising molecules that will drive the overall ATD market in the near future
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2017
Chapter 4. Global Anemia Treatment Drugs (ATD) Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Iron deficiency anemia
4.3. Thalassemia
4.4. Aplastic anemia
4.5. Hemolytic anemia
4.6. Sickle cell anemia
4.7. Pernicious anemia
Chapter 5. Global Anemia Treatment Drugs (ATD) Market, by Type of Drug, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. Supplements
5.3. Antibiotics
5.4. Immunosuppresants
5.5. Bone Marrow Stimulants
5.6. Corticosteroids
5.7. Gene Therapy
5.8. Iron Chelating Agents
5.9. Pipeline Analysis: Global ATD Market
5.9.1. Overview
5.9.2. Phase III Drugs: Market Size Forecast till 2026 (US$ Mn)
5.9.2.1. FG-4592/Roxadustat (FibroGen)
5.9.2.2. Daprodustat/GSK1278863 (GlaxoSmithKline)
5.9.2.3. Molidustat/BAY85-3934 (Bayer)
5.9.2.4. MT-6548 (Mitsubishi Tanabe Pharma Corporation)
5.9.2.5. Rivipansel/GMI-1070 (Pfizer)
5.9.2.6. Luspatercept (Celgene)
5.9.2.7. AG-348 (Agios Pharmaceuticals, Inc.)
5.9.2.8. Sutimlimab (Bioverativ Therapeutics Inc.)
5.9.2.9. V114 (Merck Sharp & Dohme Corp.)
5.9.2.10. LentiGlobin/BB305 (bluebird bio)
5.9.2.11. APL-2 (Apellis Pharmaceuticals, Inc.)
5.9.2.12. ALXN1210 (Alexion Pharmaceuticals)
5.9.2.13. OMS721 (Omeros Corporation)
5.9.3. Phase II (Tabular Representation)
5.9.4. Phase I (Tabular Representation)
Chapter 6. Global Anemia Treatment Drugs (ATD) Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America ATD Market Analysis, 2016 – 2026
6.2.1. North America ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.2.2. North America ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.2.3. North America ATD Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe ATD Market Analysis, 2016 – 2026
6.3.1. Europe ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.3.2. Europe ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.3.3. Europe ATD Market, by Country, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific ATD Market Analysis, 2016 – 2026
6.4.1. Asia Pacific ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.4.2. Asia Pacific ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.4.3. Asia Pacific ATD Market, by Country, 2016 – 2026 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest of APAC
6.5. Latin America ATD Market Analysis, 2016 – 2026
6.5.1. Latin America ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.5.2. Latin America ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.5.3. Latin America ATD Market, by Country, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) ATD Market Analysis, 2016 – 2026
6.6.1. Middle East & Africa ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.6.2. Middle East & Africa ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.6.3. MEA ATD Market, by Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA
Chapter 7. Company Profiles
7.1. Amgen, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Hoffmann-La Roche Ltd.
7.3. Novartis AG
7.4. Pfizer, Inc.
7.5. Janssen Pharmaceuticals, Inc.
7.6. Teva Pharmaceutical Industries, Ltd.
7.7. AMAG Pharmaceuticals
7.8. Rockwell Medical
7.9. Akebia Therapeutics
7.10. Vifor Pharma Management, Ltd.
7.11. FibroGen, Inc.
7.12. GlaxoSmithKline plc
7.13. Bayer AG
7.14. Omeros Corporation
7.15. Merck Sharp & Dohme Corp.
List of Figures
FIG. 1 Anemia Treatment Drugs (ATD): Market Segmentation
FIG. 2 Global ATD Market Share, by Type of Anemia, 2017 (US$ Mn)
FIG. 3 Global ATD Market Share, by Type of Drug, 2017 (US$ Mn)
FIG. 4 Global ATD Market, by Geography, 2017 Vs 2026 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography, 2017
FIG. 6 Market Competition Landscape, by Key Players, 2017
FIG. 7 Global Iron Deficiency ATD Market, 2016 – 2026 (US$ Mn)
FIG. 8 Global Thalassemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 9 Global Aplastic ATD Market, 2016 – 2026 (US$ Mn)
FIG. 10 Global Hemolytic ATD Market, 2016 – 2026 (US$ Mn)
FIG. 11 Global Sickle Cell ATD Market, 2016 – 2026 (US$ Mn)
FIG. 12 Global Pernicious ATD Market, 2016 – 2026 (US$ Mn)
FIG. 13 Global Supplements Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 14 Global Antibiotics Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 15 Global Immunosuppressant Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 16 Global Bone Marrow Stimulants Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 17 Global Corticosteroids Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 18 Global Gene Therapy Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 19 Global Iron Chelating Agents Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 20 U.S. ATD Market, 2016 – 2026 (US$ Mn)
FIG. 21 Canada ATD Market, 2016 – 2026 (US$ Mn)
FIG. 22 U.K. ATD Market, 2016 – 2026 (US$ Mn)
FIG. 23 Germany ATD Market, 2016 – 2026 (US$ Mn)
FIG. 24 Rest Of Europe ATD Market, 2016 – 2026 (US$ Mn)
FIG. 25 Japan ATD Market, 2016 – 2026 (US$ Mn)
FIG. 26 China ATD Market, 2016 – 2026 (US$ Mn)
FIG. 27 Rest Of Asia Pacific ATD Market, 2016 – 2026 (US$ Mn)
FIG. 28 Brazil ATD Market, 2016 – 2026 (US$ Mn)
FIG. 29 Mexico ATD Market, 2016 – 2026 (US$ Mn)
FIG. 30 Rest Of Latin America ATD Market, 2016 – 2026 (US$ Mn)
FIG. 31 GCC ATD Market, 2016 – 2026 (US$ Mn)
FIG. 32 Rest Of Middle East And Africa ATD Market, 2016 – 2026 (US$ Mn)
List of Tables
TABLE 1 Global Anemia Treatment Drugs (ATD) Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 2 Global ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 3 North America ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 4 North America ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 5 North America ATD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 6 Europe ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 7 Europe ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 8 Europe ATD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 9 Asia Pacific ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 10 Asia Pacific ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific ATD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Latin America ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 13 Latin America ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 14 Latin America ATD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 15 Middle East & Africa ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 16 Middle East & Africa ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 17 Middle East And Africa ATD Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 18 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Hoffmann-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Pfizer, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Janssen Pharmaceuticals, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Teva Pharmaceutical Industries, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 AMAG Pharmaceuticals : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Rockwell Medical : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 Akebia Therapeutics : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 27 Vifor Pharma Management, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 28 FibroGen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 29 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 30 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 31 Omeros Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 32 Merck Sharp & Dohme Corp. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)